Boehringer Ingelheim: all 2,305 studies
Page 21 of 24. Open to participants first (62), then studies with results posted, then the rest; newest registration first within each.
- Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's DiseaseCompletedNCT02172573Phase 3
- A Collection of Vital Status and Pulmonary Medication Usage Data for Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Withdrew Prematurely From Tiotropium Inhalation Solution Delivered by the Respimat InhalerCompletedNCT02172560
- Effect of Spiriva® on Health-related Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients Who Stopped Smoking During Treatment.CompletedNCT02172547
- Safety, Tolerability and Pharmacokinetics of Tiotropium in Cystic Fibrosis PatientsCompletedNCT02172534Phase 1
- Effect of Spiriva® 18 Microgram on Health-related Quality of Life and Physical Functioning in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Proven HyperinflationCompletedNCT02172521
- Effect of Tiotropium Inhalation Capsules on Exercise Tolerance, Daily Activity and Dyspnoea in Patients With Chronic Obstructive Pulmonary Disease (COPD) Participating in 3 Weeks of Pulmonary RehabilitationTerminatedNCT02172508Phase 4
- Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Daily PracticeCompletedNCT02172495
- Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02172482
- Efficacy and Safety of Tiotropium and Atrovent in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02172469Phase 3
- Evaluation of the Lung Deposition Rate and Distribution Pattern of Tiotropium Via HandiHalerTM in Healthy Subjects and Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02172456Phase 3
- Comparison of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (MDI) in a Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary DiseaseCompletedNCT02172443Phase 3
- Comparison of Tiotropium Inhalation Capsules and Oxitropium Metered Dose Inhalator (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02172430Phase 3
- Tiotropium in Combination With Concomitant Cimetidine or Ranitidine in Healthy Male and Female SubjectsCompletedNCT02172417Phase 1
- HandiHaler® vs. Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02172404Phase 3
- Effect of Tiotropium on Airway Diameter in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02172391Phase 3
- 12-week Treatment With Inhaled Tiotropium (18 mcg Once Daily) on Lung Function and Static Lung Volumes in Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients. Correlation to Dyspnoea ScalesCompletedNCT02172378Phase 3
- Dose Ranging Study of Ba 679 BR Inhalation Powder in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT02172352Phase 2
- The Pharmacokinetic, Safety and Tolerability of Tiotropium in Outpatients With Renal Impairment in Comparison to Healthy SubjectsCompletedNCT02172339Phase 1
- Pharmacokinetic Study in Elderly Patients With Chronic Obstructive Bronchitis (COPD)CompletedNCT02172326Phase 3
- Effect of Tiotropium on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02172300Phase 3
- Multiple Dose Comparison of Tiotropium Inhalation Capsules, Salmeterol Inhalation Aerosol and Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02172287Phase 3
- BI 10773 Administered as Oral Solution to Healthy Male VolunteersCompletedNCT02172274Phase 1
- Relative Bioavailability of BI 10773 and Glimepiride in Healthy Male VolunteersCompletedNCT02172261Phase 1
- Relative Bioavailability BI 10773 and Metformin in Healthy Male VolunteersCompletedNCT02172248Phase 1
- Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy VolunteersCompletedNCT02172235Phase 1
- Relative Bioavailability of BI 10773 and Linagliptin in Healthy Male VolunteersCompletedNCT02172222Phase 1
- Bioavailability and Pharmacokinetics of BI 10773 Tablet in Healthy Male VolunteersCompletedNCT02172209Phase 1
- Bioavailability of BI 10773 and Sitagliptin in Healthy Male VolunteersCompletedNCT02172196Phase 1
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 10773 in Healthy Male SubjectsCompletedNCT02172170Phase 1
- Investigation of the Metabolism and Pharmacokinetics of [14C]BI 1744 CL and [14C]BI 1744 CL Administered as an Oral Solution in Healthy Male SubjectsCompletedNCT02172157Phase 1
- Via Respimat® Inhaled BI 1744 CL Compared to Moxifloxacin and Placebo in Healthy Male and Female VolunteersCompletedNCT02172144Phase 1
- Safety, Tolerability and Pharmacokinetics Study of BI 1744 CL in Healthy Male SubjectsTerminatedNCT02172131Phase 1
- BI 1744 CL in Patients With Severe Renal Impairment in Comparison to Subjects With Normal Renal FunctionCompletedNCT02172118Phase 1
- Multiple Rising Inhalative Doses of BI 1744 CL in Healthy Male VolunteersCompletedNCT02172105Phase 1
- Single Dose of BI 1744 CL in Patients With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic FunctionCompletedNCT02171832Phase 1
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BI 1744 CL in Healthy Male and Female VolunteersCompletedNCT02171806Phase 1
- Single Rising Peroral Doses of BI 1744 CL in Healthy VolunteersCompletedNCT02171793Phase 1
- A Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 1744 CL in Healthy Male and Female VolunteersCompletedNCT02171780Phase 1
- Safety and Tolerability of 4 Different Dosage Strengths of BIBW 2992 Tablets to Healthy Male VolunteersCompletedNCT02171767Phase 1
- Relative Bioavailability of a Single-dose Administration of BIBW 2992 and Multiple-dose Administration of Ritonavir in Healthy VolunteersCompletedNCT02171754Phase 1
- Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid TumorsCompletedNCT02171741Phase 1
- Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid TumorsCompletedNCT02171728Phase 1
- BIBW 2992 Administered as Tablet (Final Formulation) Compared to BIBW 2992 Drinking Solution and BIBW 2992 Tablet (Trial Formulation II) in Healthy Male VolunteersCompletedNCT02171715Phase 1
- Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid TumoursCompletedNCT02171702Phase 1
- Metabolism and Pharmacokinetics of [14C]- BIBW 2992 MA2 in Healthy Male VolunteersCompletedNCT02171689Phase 1
- BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid TumorsCompletedNCT02171676Phase 1
- Dose Escalation Study of BIBW 2992 in Patients With Advanced Solid TumorsCompletedNCT02171663Phase 1
- BIBW 2992 in Patients With Advanced Solid TumorsCompletedNCT02171650Phase 1
- Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid TumorsCompletedNCT02171637Phase 1
- Safety and Pharmacokinetics of Quinidine Alone and in Combination With Dabigatran EtexilateCompletedNCT02171624Phase 1
- Investigation of the Impact of Concomitant Use of Multiple Doses of Clopidogrel With Multiple Doses of Dabigatran Etexilate on the Pharmacokinetic and Pharmacodynamic Parameters in Healthy Male SubjectsCompletedNCT02171598Phase 1
- Bioavailability of Dabigatran With or Without Clarithromycin in Healthy VolunteersCompletedNCT02171585Phase 1
- Single and Multiple Oral Doses of Dabigatran Etexilate in Healthy Chinese SubjectsCompletedNCT02171572Phase 1
- Relative Bioavailability and Pharmacodynamics of Dabigatran With Enoxaparin in Healthy Male and Female VolunteersCompletedNCT02171559Phase 1
- Relative Bioavailability of Dabigatran Etexilate Capsules With and Without Quinidine Sulfate Tablets and to Measure the Effect of Quinidine on the Absorption of Fexofenadine in Healthy Male and Female VolunteersTerminatedNCT02171546Phase 1
- Relative Bioavailability of Single Oral Doses of Dabigatran Etexilate With or Without Oral Administration of Verapamil in Two Different Dosages in Healthy Male and Female VolunteersCompletedNCT02171533Phase 1
- Bioequivalence of Two Different Generations of Drug Product of Dabigatran Etexilate Following Oral Administration in Healthy Male and Female VolunteersCompletedNCT02171520Phase 1
- Relative Bioavailability of Dabigatran and Diclofenac After Dabigatran Etexilate and Diclofenac Single Dose Alone or Following Concomitant Multiple Oral Administrations in Healthy Male and Female VolunteersCompletedNCT02171507Phase 1
- Bioequivalence of IVAX Warfarin Tablets and Coumadin Brand Warfarin Tablets in Healthy VolunteersCompletedNCT02171494Phase 1
- Bioequivalence of Two Different Polymorphs of Dabigatran Etexilate in Healthy Male and Female VolunteersCompletedNCT02171481Phase 1
- Pharmacokinetics, Safety and Pharmacodynamics After Multiple Oral Doses of Dabigatran Etexilate Capsule in Healthy Japanese and Caucasian Male SubjectsCompletedNCT02171468Phase 1
- Safety, Pharmacodynamics and Pharmacokinetics After Single Oral Administration of Dabigatran Etexilate Capsule in Healthy SubjectsCompletedNCT02171455Phase 1
- Metabolism and Pharmacokinetics of [14C]-BIBR 953 ZW After Administration of Single Doses of [14C]-BIBR 953 ZW Intravenously or [14C]-BIBR 1048 Oral Solution in Healthy Male VolunteersCompletedNCT02171442Phase 1
- Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis (EAP)Approved for marketingNCT02171156
- Relative Bioavailability of Dabigatran and Digoxin in Healthy Male and Female VolunteersCompletedNCT02171052Phase 1
- Relative Bioavailability of Dabigatran and Atorvastatin in Healthy Male and Female VolunteersCompletedNCT02171039Phase 1
- Bioavailability of Dabigatran and Amiodarone After Multiple Oral Administrations of Dabigatran Etexilate With or Without Amiodarone as Single Dose in Healthy Male and Female VolunteersCompletedNCT02171026Phase 1
- Bioequivalence of Two Different Drug Product Batches of Dabigatran Etexilate Following Oral Administration in Healthy Male and Female VolunteersCompletedNCT02171013Phase 1
- Safety, Pharmacokinetics and Pharmacodynamics After Multiple Oral Doses of BIBR 1048 MS Capsule in Healthy Japanese Male SubjectsCompletedNCT02171000Phase 1
- Assessment of Electrophysiological Effects of Dabigatran Etexilate as Single Dose on the QT Interval in Healthy Female and Male Subjects.CompletedNCT02170987Phase 1
- Bioavailability of BIBR 953 ZW After BIBR 1048 (Oral Pro-drug of BIBR 953 ZW) Administered as Hydroxypropyl Methylcellulose (HPMC) Polymorph II Capsule Relative to HPMC Polymorph I Capsule in Healthy Subjects.CompletedNCT02170974Phase 1
- Pharmacokinetic (PK) Assessment of BIBR 1048 in Patients After Primary Elective Total Hip Replacement SurgeryCompletedNCT02170935Phase 2
- Bioavailability of BIBR 1048 MS Tablets in Healthy Subjects With or Without FoodCompletedNCT02170922Phase 1
- Safety, Pharmacokinetics and Pharmacodynamics of BIBR 1048 MS Capsule in Healthy Male Subjects of Japanese and Caucasian OriginCompletedNCT02170909Phase 1
- Bioavailability of BIBR 963 ZW After 50 mg of BIBR 1048 MS With and Without of Pantoprazole in Healthy SubjectsCompletedNCT02170896Phase 1
- Safety, Pharmacokinetics and Pharmacodynamics After Single Rising Oral Doses of BIBR 1048 MS as Capsules in Healthy Subjects of Japanese and Caucasian OriginCompletedNCT02170844Phase 1
- Multiple Oral Doses of BIBR 1048 MS Solution in Healthy VolunteersCompletedNCT02170831Phase 1
- Bioavailability of BIBR 1048 MS Single Doses With or Without Pantoprazole in Healthy SubjectsCompletedNCT02170805Phase 1
- Bioavailability of BIBR 953 ZW After Dose of BIBR 1048 MSCompletedNCT02170792Phase 1
- Bioavailability of BIBR 953 ZW in Healthy SubjectsCompletedNCT02170766Phase 1
- Assessment of Safety, Pharmacokinetics and the Effect of BIBR 1048 MS on Coagulation Parameters in Healthy Volunteer SubjectsCompletedNCT02170740Phase 1
- BIBR 1048 in the Prevention of Venous Thromboembolism in Patients Undergoing Primary Elective Total Hip Replacement SurgeryCompletedNCT02170701Phase 2
- Relative Bioavailability of Single Doses of Dabigatran Etexilate When Administered Alone or in Combination With a Single Dose of Ketoconazole or in Combination With q.d. Ketoconazole at Steady State in Healthy Male and Female VolunteersCompletedNCT02170675Phase 1
- Bioavailability of BIBR 953 ZW After Oral Administration of BIBR 1048 MS in Healthy SubjectsCompletedNCT02170636Phase 1
- Bioavailability of BIBR 953 ZW After Administration of BIBR 1048 MS in Healthy SubjectsCompletedNCT02170623Phase 1
- Bioavailability of BIBR 1048 MS With and Without Pantoprazole Under Influence of Food in Healthy SubjectsCompletedNCT02170610Phase 1
- Bioavailability of BIBR 953 ZW Under Influence of Food in Healthy SubjectsCompletedNCT02170597Phase 1
- Tolerability of BIBR 953 ZW IV and Bioavailability of BIBR 1048 Tablet and Solution in Healthy MalesCompletedNCT02170584Phase 1
- Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic FunctionCompletedNCT02170571Phase 1
- Pharmacodynamics, Safety and Pharmacokinetics After Oral Administration of BIBR 1048 MS in Healthy VolunteersCompletedNCT02170116Phase 1
- Relative Bioavailability of a BI 187004 Tablet Formulation in Comparison With an Oral Solution and the Influence of Food on the Tablet Formulation in Healthy VolunteersCompletedNCT02161432Phase 1
- Safety and Tolerability, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Three Doses of BI 187004 Over 28 Days in Patients With Type 2 Diabetes Mellitus With and Without MetforminCompletedNCT02150824Phase 2
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 639667WithdrawnNCT02133482Phase 1
- Multiple Rising Oral Doses of BI 1060469 in Healthy Subjects and Mild Asthma PatientsCompletedNCT02126865Phase 1
- A Study to Investigate the Phototoxic Potential of FaldaprevirWithdrawnNCT02114671Phase 1
- Relative Bioavailability of Multiple Oral Doses of BI 187004 and Metformin After Co-administration Compared to Multiple Oral Doses of BI 187004 Alone and Metformin Alone in Healthy Male SubjectsCompletedNCT02109679Phase 1
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI 1181181 in Healthy Male VolunteersCompletedNCT02106247Phase 1
- Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181CompletedNCT02044406Phase 1
- Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 DiabetesWithdrawnNCT01984606Phase 3
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses and Effect of Food on the Bioavailability of BI 1060469CompletedNCT01971502Phase 1